NEWS & MEDIA · February 4, 2025
As major insulin producers shift focus, rBIO steps up to address potential shortages
This article summarizes coverage published on February 4, 2025.
Company update
In its February 2025 announcement, rBIO reported preclinical progress for R-biolin and described its plans to increase manufacturing scale. The company framed this work around the need for a reliable supply of affordable human insulin.
The announcement also discussed the impact of discontinued insulin formulations and the company’s interest in developing additional biosimilar options. Partnerships and further validation were identified as steps toward larger-scale production.
This is an archived news summary; development plans described here reflect the original publication date.